Phaseline

Companies › Dong-A ST

Dong-A ST: clinical trials, targets and expected readouts

4 active drug programs in 4 registered trials: 2 Phase 1, 1 Phase 4, 1 Phase 3; Oncology, Gastroenterology, Metabolic and endocrine; next expected readout Oct 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
DA-9701-R–Phase 4Functional DyspepsiaOct 2027
DA5221-T
SGLT-2 inhibitor
SLC5A2Phase 3Type 2 Diabetes–
DA-3501
anti-CLDN18.2 antibody-drug conjugate
CLDN18Phase 1Gastric (Stomach) CancerFeb 2028
DA-4505–Phase 1Locally Advanced or Metastatic Solid TumorsOct 2029

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06290349DA5221-TPhase 3Type 2 DiabetesMetabolic and endocrineSep 2025
NCT07686679DA-9701-RPhase 4Functional DyspepsiaGastroenterologyOct 2027
NCT07481357DA-3501Phase 1Gastric (Stomach) CancerOncologyFeb 2028
NCT06293651DA-4505Phase 1Locally Advanced or Metastatic Solid TumorsOncologyOct 2029

Targets

SLC5A2 (1) CLDN18 (1)

Companies with the same targets

AstraZeneca Astellas THPharm Boryung Pharmaceutical Lexicon Pharmaceuticals Getz Pharma Boehringer Ingelheim Hangzhou Zhongmei Huadong Pharmaceutical JW Pharmaceutical RemeGen

Companies built like this

Biokin (Shanghai) Biopharmaceutical Hangzhou Sumgen Biotech LaNova Medicines Zhejiang Xuanzhu Biopharmaceutical InxMed (Shanghai)

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.